Skip to main content
OpenTrials
Completed

NCT Number: NCT03873324

Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers

The planned study is to determine the safety and pharmacokinetic properties of CPL500036 compound after single and multiple (two weeks) administration in healthy volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteers

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

BioResearch Group Sp. z o.o.

Kajetany, Nadarzyn, 05-830, Poland

About this study

This is to be one-centre, single ascending dose and double-blind multiple ascending dose two part study of CPL500036 compound in healthy volunteers.

PART A is a single dose, open-label part with CPL500036 compound administered with dose escalation between cohorts.

PART B is a multiple, double-blind part with CPL500036 compound administered for 14 days with dose escalation between cohorts. Participants in this part are to be randomized to receive Investigational Medicinal Product (IMP) or placebo in 3:1 ratio.

Safety and pharmacokinetic properties of CPL500036 compound is to be determined following different doses in single oral IMP administration in PART A and different doses of IMP administered orally for two weeks in PART B.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Caucasian female or male,
  • Age: 18-55 years old, inclusive,
  • Body-mass index (BMI): ≥18.5 kg/m^2 and <29.9 kg/m^2,
  • Non-smoker and nonuser of tobacco products for at least 3 months before screening,
  • Physical examination without any clinically relevant abnormality,
  • Laboratory values not clinically significant,
  • Volunteer (or his/her partner) of childbearing potential willingness to use acceptable forms of contraception.

Exclusion criteria

  • Known allergy or hypersensitivity to other drugs similar in structure or class to CPL500036 compound, or to any excipients of the formulation,
  • Any known significant current or past acute or chronic disease or condition,
  • Participation in other clinical trial within 90 days preceding the screening,
  • Blood drawn within 30 days prior to inclusion to the study (more or equal to 300mL),
  • Positive results from pregnancy test for female participants,
  • Lactation in women participants,
  • Hypotension or hypertension in medical history,
  • Long QT interval syndrome or is under the treatment with antiarrhythmic drugs,
  • Narcotic, alcohol addiction or abuse,
  • Participant who adhere to a special diet (e.g. low calories, vegetarian).

Treatment and study plan

CPL500036 compound

Drug

IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).

Placebo

Drug

matching placebo capsules

Primary outcomes

  1. Determination of maximum tolerated dose (MTD) or administration of the maximum dose provided in the protocol after single and multiple oral administration of IMP.

    Time frame: up to 24 hours after single administration of IMP in PART A and up to 24 hours after the last IMP administration in PART B

    MTD is defined as the highest dose for which no more than 1 of the 6 treated volunteers (less than 1/3) exhibits dose limiting toxicity (DLT).

  2. Safety and tolerability of IMP after single and multiple oral administration based on laboratory values, vital signs, ECG, physical examinations and Adverse Events monitoring.

    Time frame: up to 14 days in PART A and up to 28 days in PART B of the study

    Participants are to be closely observed to assure maximal safety and to collect occurrence of all adverse events. All participants are to be monitored for clinically relevant changes in physical examination, vital signs, 12-lead ECG assessment and deviations from normal in clinical laboratory results (complete blood count, blood chemistry, urinalysis). To follow-up on all study participants telephone calls with a request for information regarding their health condition are to be made.

Secondary outcomes

  1. Cmax - maximum CPL500036 plasma concentration

    Time frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B

    The maximum concentration of the CPL500036 compound in plasma after IMP administration, obtained directly from the measured concentrations.

  2. AUC(0-72) - area under the plasma concentration - time curve from time 0 to 72h after IMP administration for CPL500036

    Time frame: up to 72 hours after administration of IMP in PART A

    The AUC(0-72) is a measure of total plasma exposure to the drug from time point zero to 72 hours after IMP administration.

  3. AUC(0-24) - area under the plasma concentration - time curve from time 0 to 24h after IMP administration for CPL500036

    Time frame: up to 24 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 and 14 in PART B

    The AUC(0-24) is a measure of total plasma exposure to the drug from time point zero to 24 hours after IMP administration.

  4. AUC(0-inf) - area under the plasma concentration - time curve from time 0 to infinity time for CPL500036

    Time frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B

    The AUC(0-inf) is a measure of total plasma exposure to the drug from time point zero extrapolated to infinity.

  5. Tmax - time to reach maximum CPL500036 concentration

    Time frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B

    The Tmax is time to reach the maximum plasma concentration (Cmax), obtained directly from the actual sampling times.

  6. Kel - terminal elimination rate constant

    Time frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B

    Kel is to be estimated via linear regression of time versus log of concentration.

  7. T1/2 - The plasma elimination half-life for CPL500036 compound

    Time frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B

    T1/2 is to be calculated as 0.693/Kel.

  8. C (1,t) - CPL500036 concentration

    Time frame: Determined on Day 2, 3, 4, 5, 6, 8, 9, 10, 11, 12 and 13 in PART B.

    The concentration of CPL500036 on day t before product administration.

  9. C (Tmax, t) - CPL500036 concentration

    Time frame: Determined on Day 2, 3, 4, 5, 6, 8, 9, 10, 11, 12 and 13 in PART B.

    The concentration on day t measured on time Tmax which was calculated in PART A of the study.

  10. Amount of CPL500036 in each urine collection sample

    Time frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B

    It is to be calculated as CPL500036 concentration in urine sample times volume of urine collection.

  11. Ae - total amount of CPL500036 excreted in urine

    Time frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B

    Ae is to be calculated as asymptote of the plot of the cumulative amount of drug excreted after each collection interval plotted against the median of the collection interval.

  12. Clr - renal clearance

    Time frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B

    Clr is to be calculated by linear least squares regression analysis on semi-logarithmic transformed data (CLr = excretion rate/C).

  13. Excretion rate

    Time frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B

    Excretion rate calculated as = CLr/V x Dose x exp(-kt)

Sponsors and collaborators

Lead sponsor

Celon Pharma SA

Industry

Collaborators

  • National Center for Research and Development, Poland

Registry information

Official study title

One Centre Single Ascending Dose and Double Blind Multiple Ascending Dose, Safety and Pharmacokinetics Phase I Study of CPL500036 Compound in Healthy Volunteers

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Mar 13, 2019
Registry last updated
Oct 4, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.